Nieren- und leberinsuffiziente Patienten — ein therapeutisches Problem

  • H. P. Kapfhammer
Conference paper

Zusammenfassung

Der Einsatz von Psychopharmaka bei Patienten mit einer psychiatrischen und einer somatischen Erkrankung erfordert eine sorgfältige Abwägung von möglichen Nutzen und Risiken. Besondere Probleme können sich ergeben, wenn 1. pathophysiologische Prozesse einer vorliegenden somatischen Erkrankung zu bedeutsamen Veränderungen im Metabolismus psychotroper Substanzen führen, 2. das jeweils typische Nebenwirkungsprofil eines Psychopharmakons sich auf die Grunderkrankung selbst verschlimmernd auswirkt und 3. störende Interaktionseffekte mit notwendigen internistischen Medikamenten erwartet werden können (Stoudemire et al. 1990, 1991). Entsprechend der zentralen Rolle von Leber und Niere in der Verstoffwechselung und Ausscheidung von Pharmaka müssen bei Patienten mit Leber- bzw. Niereninsuffizienz auch spezielle Überlegungen bei einer Psychopharmakatherapie angestellt werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Alfrey A (1986) Dialysis encephalopathy. Kidney Int 29 [Suppl]: 53–57Google Scholar
  2. Alfrey A, Mishell JM, Burks J, Contigulia SR, Rudolph H, Lewin E, Homes JH (1972) Syndrome of dyspraxia and multifocal seizures associated with chronic hemodialysis. Trans Am Soc Artif Intern Org 18: 257–261Google Scholar
  3. Abram HS, Moore GL, Westervelt GV (1971) Suicidal behavior in chronically dialyzed patients. Am J Psychiatry 127: 1199–1204PubMedGoogle Scholar
  4. Arieff AI (1981) Neurological complications of uremia. In: Brennan B, Rector F (eds) The kidney. Saunders, Philadelphia, pp 2307–2343Google Scholar
  5. Bennett WM (1986) Drugs and renal disease, 2nd edn. Churchill Livingstone, Edinburgh London Melbourne New YorkGoogle Scholar
  6. Bennett WM, Aronoff GR, Golper TA, Morrison G, Singer I, Brater DC (1987) Drug prescribing in renal failure: Dosing guidelines for adults. American College of Physicians, PhiladelphiaGoogle Scholar
  7. Blackwell B (1981) Adverse effects of antidepressant drugs. Drugs 21: 201–209, 273–282PubMedCrossRefGoogle Scholar
  8. Bonhoeffer K (1909) Exogene Psychosen. Zentralbl Nervenheilkd 32: 499–505Google Scholar
  9. Bonhoeffer K (1910) Die symptomatischen Psychosen im Gefolge von akuten Infectionen und inneren Erkrankungen. Deuticke, LeipzigGoogle Scholar
  10. Branch RA (1987) Is there increased cerebral sensitivity to benzodiazepine in chronic liver disease? Hepatology 7: 773–776PubMedCrossRefGoogle Scholar
  11. Brater DC (1991) Dosing regimens in renal disease. In: Jacobson HR, Striker GE, Klahr S (eds) The principles and practice of nephrology. Decker, Philadelphia Hamilton, pp 874–882Google Scholar
  12. Burnett GB, McKee DC, Raft D, Lipton MA, Blythe WB (1980) Neuropsychiatric syndromes in hemodialysis: A review. Dial Transplant 9: 925–926Google Scholar
  13. Cheng YF, Lundberg T, Bondesson U et al. (1988) Clinical pharmacokinetics of clozapine in chronic schizophrenia. Eur J Clin Pharmacol 34: 445–449PubMedCrossRefGoogle Scholar
  14. Craven J, Rodin G, Johnson L et al. (1987) The diagnosis of major depression in renal dialysis patients. Psychosom Med 49: 482–492PubMedGoogle Scholar
  15. DasGusta K, Jefferson JW (1990) The use of lithium on the medically ill. Gen Hosp Psychiatry 12: 83–97CrossRefGoogle Scholar
  16. Dawling S, Lynn K, Rosser R et al. (1982) Nortriptyüne metabolism in chronic renal failure: Metabolite elimination. Clin Pharmacol Ther 32: 322–329PubMedCrossRefGoogle Scholar
  17. Dettli L (1983) Arzneimitteldosierung bei Nieren- und Leberinsuffizienz. Therapiewoche 33: 407–420Google Scholar
  18. Dickes R, Schenker V, Deutsch L (1957) Serial liver function and blood studies in patients receiving chlorpromazine. N Engl J Med 256: 1–7PubMedCrossRefGoogle Scholar
  19. Eigler J, Dobbelstein H (1991) Arzneimitteldosierung und -nebenwirkungen bei chronischer Niereninsuffizienz. Dt Ärztebl 88: 2163–2170Google Scholar
  20. Fowler JM, Schafer DM (1981) A mechanism for the increased sensitivity to benzodiazepines in hepatocellular failure: Evidence from an animal model. Gastroenterology 80: 1359Google Scholar
  21. Gross MLP, Pearson R, Sweny P et al. (1981) Rejection encephalopathy. Proc Eur Dial Transplant Assoc 18: 461–464PubMedGoogle Scholar
  22. Gundersen H, Amidsen A (1969) The electrophoretic pattern of alkaline phosphatase in schizophrenic females under longterm treatment with neuroleptic drugs and in young and old healthy women. Scand J Clin Lab Invest 24: 173–177PubMedCrossRefGoogle Scholar
  23. Haenel T, Brunner F, Battegay R (1980) Renal dialysis and suicide: Occurrence in Switzerland and Europe. Compr Psychiatry 21: 140–145PubMedCrossRefGoogle Scholar
  24. Hart RP, Kreutzer JS (1988) Renal system. In: Tarter RE, van Thiel DH, Edwards KL (eds) Medical neuropsychology. The impact of disease on behavior. Plenum Press, New York London, pp 99–120Google Scholar
  25. Hegedus AM, Tarter RE, van Thiel DH, Schade RR, Gavaler JS, Starzl TE (1984) Neuropsychiatric associated with primary biliary cirrhosis. Int J Psychiatry Med 14: 303–314CrossRefGoogle Scholar
  26. Hinrichsen GA, Lieberman JA, Pollack S et al. (1989) Depression in hemodialysis patients. Psycho-somatics 30: 284–289Google Scholar
  27. Hong BA, Smith MD, Robson AM, Wetzel RD (1987) Depressive symptomatology and treatment in patients with end-stage renal disease. Psychol Med 17: 185–190PubMedCrossRefGoogle Scholar
  28. House RM, Thompson TL (1988) Psychiatric aspects of organ transplantation. JAMA 260: 535–540PubMedCrossRefGoogle Scholar
  29. House RM, Trzepacz PT, Thompson TL (1990) Psychiatric consultation to organ transplant services. Rev Psychiatry 9: 515–535Google Scholar
  30. Hoyumpa AM (1986) The unfolding GABA story. Hepatology 6: 1042–1044PubMedCrossRefGoogle Scholar
  31. Jefferson J, Marshall (1981) Neuropsychiatric features of medical disorders. Plenum Press, New YorkGoogle Scholar
  32. Jones EA, Schafer DF, Ferenci P, Pappas SC (1984) The neurobiology of hepatic encephalopathy. Hepatology 4: 1235–1242PubMedCrossRefGoogle Scholar
  33. Kapfhammer HP (1993) Die psychopharmakologische Behandlung von ängstlich-depressiven Syndromen im Kontext somatischer Erkrankungen. In: Möller HJ (Hrsg) Therapie psychiatrischer Erkrankungen. Enke, StuttgartGoogle Scholar
  34. Katon W, Sullivan MD (1990) Depression in chronic medical illness. J Clin Psychiatry 51 [Suppl 6]: 3–11PubMedGoogle Scholar
  35. Koechelef JA, Canafax DM, Simmons RL et al. (1986) Lithium dosing in renal allograft recipients with changing renal function. Drug Intell Clin Pharm 20: 623–624Google Scholar
  36. Kuntz E (1992) Hepatische Enzephalopathie. Psychometrische Tests zur Diagnose, Bewertung und Therapiekontrolle in der Praxis. Münch Med Wochenschr 134: 76–80Google Scholar
  37. Leevy C (1974) Exploring the brain-liver relationship. Mod Med 42: 17–22Google Scholar
  38. Leipzig RM (1990) Psychopharmacology in patients with hepatic and gastrointestinal disease. Int J Psychiatry Med 22: 109–139CrossRefGoogle Scholar
  39. Levenson JL, Glocheski S (1991) Psychological factors affecting end-stage renal disease. Psychosomatics 32: 382–389PubMedGoogle Scholar
  40. Levinson DF, Simpson GM (1987) Serious nonextrapyramidal adverse effects of neuroleptics: Sudden death, agranulocytosis, and hepatotoxicity. In: Meltzer HY (ed) Psychopharmacology: The third generation of progress. Raven Press, New York, pp 1431–1436Google Scholar
  41. Levy NB (1985) The use of psychotropics in patients with kidney failure. Psychosomatics 26: 699–709PubMedGoogle Scholar
  42. Levy NB (1987) Chronic renal disease, dialysis, and transplantation. In: Stoudemire A, Fogel BS, Orlando FL (eds) Principles of medical psychiatry. Grune & Stratton, New York, pp 583–593Google Scholar
  43. Levy NB (1990) Psychopharmacology in patients with renal failure. Int J Psychiatry Med 20: 325–334PubMedCrossRefGoogle Scholar
  44. Lieber C, Leo M (1982) Alcohol and the liver. In: Lieber C (ed) Medical disorders of alcoholism: Pathogenesis and treatment. Saunders, Philadelphia, pp 219–312Google Scholar
  45. Lieberman JA, Cooper TB, Suckow RF, Steinberg H, Borenstein M, Brenner R, Kane JM (1985) Tricyclic antidepressant and metabolite levels in chronic renal failure. Clin Pharmacol Ther 37: 301–307PubMedCrossRefGoogle Scholar
  46. Lieberman JA, Kane JM, Johns CA (1989) Clozapine: Guidelines for clinical management. J Clin Psychiatry 50: 329–338PubMedGoogle Scholar
  47. Martini GA (1983) Leberkrankheiten. In: Riecker G (Hrsg) Therapie innerer Krankheiten. Springer, Berlin Heidelberg New York Tokyo, S 534–541Google Scholar
  48. Morgan MH, Read AE (1972) Antidepressants and liver disease. Gut 13: 697–701PubMedCrossRefGoogle Scholar
  49. O’Hare JA, Callaghan NM, Murnaghan DJ (1983) Dialysis encephalopathy. Medicine 62: 129–141PubMedGoogle Scholar
  50. Parsons-Smith B, Summerskill W, Dawson A, Sherlock S (1957) The electroencephalograph in liver disease. Lancet II: 867–871CrossRefGoogle Scholar
  51. Peterson RA, Kimmel PL, Sacks CR, Mesquita ML, Simmens SJ, Reiss D (1991) Depression, perception of illness and mortality in patients with end-stage renal disease. Int J Psychiatry Med 21: 343–354PubMedCrossRefGoogle Scholar
  52. Port FK, Kroll PD, Rosenzweig J (1979) Lithium therapy during maintenance hemodialysis. Psycho-somatics 20: 130–131Google Scholar
  53. Read A, Sherlock S, Laidlaw, Walker J (1967) The neuropsychiatric syndromes associated with chronic liver disease and extensive portal-systemic collateral circulation. Quart J Med 36: 135–150Google Scholar
  54. Secor JW, Schenker S (1987) Drug metabolism in patients with liver disease. Adv Intern Med 32: 379–406PubMedGoogle Scholar
  55. Sellers EM, Bendayan R (1987) Pharmacokinetics of psychotropic drugs in selected patient populations. In: Meltzer HY (ed) Psychopharmacology: The third generation of progress. Raven Press, New York, pp 1397–1406Google Scholar
  56. Seyffart G (1991) Drug dosage in renal insufficiency. Kluwer, Dordrecht Boston LondonCrossRefGoogle Scholar
  57. Sherlock S, Summerskill W, White L, Pheur E (1954) Portosystemic encephalopathy. Neurological complications of liver disease. Lancet II: 453–457CrossRefGoogle Scholar
  58. Smith MD, Hong BA, Robson AM (1985) Diagnosis of depression in patients with end-stage renal disease. Am J Med 79: 160–166PubMedCrossRefGoogle Scholar
  59. Solomon S, Hotchkiss E, Saravay SM, Bayer C, Ramsey P, Blum RS (1983) Impairment of memory function by antihypertensive medication. Arch Gen Psychiatry 40: 1109–1112PubMedGoogle Scholar
  60. Stoudemire A, Moran MG, Fogel BS (1990) Psychotropic drug use in the medically ill: Part I. Psychosomatics 31: 377–391PubMedGoogle Scholar
  61. Stoudemire A, Moran MG, Fogel BS (1991) Psychotropic drug use in the medically ill: Part II. Psychosomatics 32: 34–46PubMedGoogle Scholar
  62. Stricker BH, Spelstra P (1985) Drug-induced hepatic injury. Elsevier, AmsterdamGoogle Scholar
  63. Sugimoto T, Rosansky SJ (1984) The incidence of treated end-stage renal disease in the Eastern United States: 1973–1979. Am J Public Health 74: 14–17PubMedGoogle Scholar
  64. Summerskill W, Davidson E, Sherlock S, Steiner R (1956) The neuropsychiatrie syndrome associated with hepatic cirrhosis and an extensive portal collateral circulation. Quart J Med 25: 245–266PubMedGoogle Scholar
  65. Surman OS (1989) Psychiatric aspects of organ transplantation. Am J Psychiatry 146: 972–982PubMedGoogle Scholar
  66. Surman OS (1991) Hemodialysis and renal transplantation. In: Cassem NH (ed) Massachusetts General Hospital handbook of general hospital psychiatry, 3rd edn. PSG, Littleton/MA, pp 401–430Google Scholar
  67. Tarter RE, Hegedus AM, van Thiel DH, Schade RR, Galaver JS, Starzl TE (1984) Nonalcoholic cirrhosis associated with neuropsychological dysfunction in the absence of overt evidence of hepatic encephalopathy. Gastroenterology 86: 1421–1427PubMedGoogle Scholar
  68. Tarter RE, Hegedus AM, van Thiel DH, Schade RR (1985) Portosystemic encephalopathy: Neuropsychiatrie manifestations. Int J Psychiatry Med 15: 265–275PubMedCrossRefGoogle Scholar
  69. Tarter RE, Edwards KL, van Thiel DH (1988) Neuropsychological dysfunction due to liver disease. In: Tarter RE, Van Thiel DH, Edwards KL (eds) Medical neuropsychology. The impact of disease on behavior. Plenum Press, New York London, pp 75–97Google Scholar
  70. Trzepacz PT, Brenner RP, Coffman G, van Thiel DH (1988) Delirium in liver transplantation candidates: Discriminant analysis of multiple test variables. Biol Psychiatry 24: 3–14PubMedCrossRefGoogle Scholar
  71. Trzepacz PT, Brenner R, van Thiel DH (1989) A psychiatric study of 247 liver transplantation candidates. Psychosomatics 30: 147–153PubMedGoogle Scholar
  72. Trzepacz PT, Levenson JL, Tringali RN (1991) Psychopharmacology and neuropsychiatrie syndromes in organ transplantation. Gen Hosp Psychiatry 13: 233–245PubMedCrossRefGoogle Scholar
  73. Zieve L (1979) Hepatic encephalopathy: Summary of present knowledge with an elaboration on recent developments. In: Popper H, Schaffner F (eds) Progress in liver disease. Grune & Stratton, New York, pp 88–104Google Scholar
  74. Zimmerman HJ (1990) Update of hepatotoxicity due to classes of drugs in common clinical use: Non-steroidal drugs, anti-inflammatory drugs, antibiotics, antihypertensives, and cardiac and psychotropic agents. Semin Liver Dis 10: 322–338PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • H. P. Kapfhammer

There are no affiliations available

Personalised recommendations